Few corners of the London market attract attention faster than a stock flashing an extreme momentum reading, and Advanced Medical Solutions Group plc (LSE:AMS) has done exactly that, appearing among the most overbought UK shares screened by RSI. With a 14-day RSI of 74.53 …
Feedback (FDBK) has been flagged on UK 'most undervalued' and oversold stock screens, largely because its Relative Strength Index (RSI) has fallen toward levels traders associate with oversold conditions after a period of share-price weakness. As a medical imaging and clinical data technology company, …
EDX Medical Group (EDX) has been flagged on UK 'most undervalued' and oversold stock screens, largely because its Relative Strength Index (RSI) has fallen toward levels traders associate with oversold conditions after a period of share-price weakness. As a diagnostics and precision-medicine company, its …
CRISM Therapeutics (CRTX) has been flagged on UK 'most undervalued' and oversold stock screens, largely because its Relative Strength Index (RSI) has fallen toward levels traders associate with oversold conditions after a period of share-price weakness. As a clinical-stage therapeutics company, its valuation is …
Cambridge Nutritional Sciences (CNSL) has been flagged on UK 'most undervalued' and oversold stock screens, largely because its Relative Strength Index (RSI) has fallen toward levels traders associate with oversold conditions after a period of share-price weakness. As a diagnostics and nutritional health testing …
Arecor Therapeutics (AREC) has been flagged on UK 'most undervalued' and oversold stock screens, largely because its Relative Strength Index (RSI) has fallen toward levels traders associate with oversold conditions after a period of share-price weakness. As a biopharmaceutical formulation technology company, its valuation …
Scancell Holdings plc attracted investor attention after its shares declined approximately 7.14% during trading on 25 June 2026. The move placed the biotechnology company among the notable healthcare fallers on London's AIM market and prompted investors to evaluate whether the decline reflected company-specific developments …
Provexis PLC came under selling pressure on 25 June 2026, with its shares declining approximately 9.09% during the trading session. The move placed the company among the day's notable AIM fallers and generated increased interest from retail investors seeking to understand the reasons behind …
• AIM:GENI – GENinCode Plc declined approximately 9.09% on 25 June 2026, making it one of the notable healthcare fallers on London's AIM market.
• AIM:ABDX – Abingdon Health Plc declined approximately 8.11% on 25 June 2026, making it one of the notable healthcare sector fallers on the AIM market.